

Literatura:

1. Van Gelder I C et al. European Heart Journal (2024) 45, 3314–3414
2. Kvasnička J et al. Vnitř Lék 2015; 61(6): 537–546
3. Čihák R. Praktická doporučení European Heart Rhythm Association k používání nových perorálních antikoagulancií u pacientů s fibrilací síní – aktualizace 2018. Souhrn dokumentu připravený Českou kardiologickou společností, Cor et Vasa 60 (2018) e421–e447.
4. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634–40. <https://doi.org/10.1001/jama.293.21.2634>
5. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace 2023;25:6–27. <https://doi.org/10.1093/europace/euac062>
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. <https://doi.org/10.1056/NEJMoa0905561>
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369: 2093–104. <https://doi.org/10.1056/NEJMoa1310907>
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981–92. <https://doi.org/10.1056/NEJMoa1107039>
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91. <https://doi.org/10.1056/NEJMoa1009638>
10. Mannina C, Jin Z, Matsumoto K, Ito K, Biviano A, Elkind MSV, et al. Frequency of cardiac arrhythmias in older adults: findings from the subclinical atrial fibrillation and risk of is chemic stroke (SAFARIS) study. Int J Cardiol 2021;337:64–70. <https://doi.org/10.1016/j.ijcard.2021.05.006>
11. Guidelines_praktitici_DOACS_Prakticus_2025/Postup-p%C5%99i-krv%C3%A1cen%C3%AD.pdf